Corin gene double variant (Thr555Ile and Glu568Pro) and high blood pressure risk in Afro‑Caribbean adults
STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE
This study will test whether two corin gene variants (Thr555Ile and Glu568Pro) are linked to high blood pressure in Afro‑Caribbean adults in Guadeloupe.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 370 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 2 sites (Petit-Bourg and 1 other locations) |
| Trial ID | NCT07330804 on ClinicalTrials.gov |
What this trial studies
Researchers will compare adults of Afro‑Caribbean descent with confirmed hypertension to age‑ and sex‑matched controls without hypertension, collecting clinical blood pressure data and genetic samples. DNA will be genotyped to detect the double polymorphism in the CORIN gene (Thr555Ile and Glu568Pro) and its frequency will be compared between cases and controls. Inclusion requires participants to be over 18, affiliated with a social security plan, self‑identify as Afro‑Caribbean, and provide written consent. The goal is to determine whether the double variant is a risk marker for hypertension in this specific population, which could inform future screening or prevention strategies.
Who should consider this trial
Good fit: Adults 18 or older who self‑identify as Afro‑Caribbean, are affiliated with a social security plan, can give written consent, and either have confirmed hypertension (cases) or are similar‑aged, same‑sex controls without hypertension.
Not a fit: People who are under 18, not of Afro‑Caribbean descent, not affiliated with social security, or those seeking immediate clinical treatment rather than genetic risk information are unlikely to gain direct benefit from participation.
Why it matters
Potential benefit: If a clear link is found, genetic testing for these corin variants could help identify people at higher risk for hypertension and guide earlier prevention or tailored care.
How similar studies have performed: Previous research has reported associations between related CORIN variants (including T555I/Q568P) and hypertension in African‑ancestry populations, so this work builds on existing but not yet definitive evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Case inclusion criteria * Persons affiliated with or benefiting from a social security plan; * Over 18 years of age; * Considering themselves to be of Afro-Caribbean descent; * Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research); * Treated for hypertension or presenting with hypertension according to recommendations: elevated blood pressure (BP), including systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg measured in the physician's office and confirmed over several visits on the day of inclusion or diagnosis made by ABPM or self-measurement. Control inclusion criteria: * Individuals affiliated with or benefiting from a social security plan; * Over 18 years of age; * Patients who consider themselves of Afro-Caribbean origin, of the same sex as the cases and ± 5 years of age, not treated for hypertension and not presenting with hypertension according to the HAS recommendations on the day of the inclusion visit. Controls will be recruited by the same GPs who included a person with hypertension, consulting for any other symptom * Having given their free, informed, written and signed consent (at the latest on the day of inclusion and before any examination required by the research); Exclusion Criteria: * Minors; Pregnant or breastfeeding women; Protected persons, or persons under court protection; Refusal to participate. Patients unable to come to the laboratory
Where this trial is running
Petit-Bourg and 1 other locations
- Medical practice KERIB — Petit-Bourg, Guadeloupe (Recruiting)
- Toncoeurtonka — Petit-Canal, Guadeloupe (Not_yet_recruiting)
Study contacts
- Study coordinator: HEDREVILLE SEGO, Doctor
- Email: hedrevillesego.cabinet@orange.fr
- Phone: +590 590 386355
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.